Clinical Trial

Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class B7 Cirrhosis

Study acronym: LIVERATION
Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated April 29, 2025 (before its estimated February 2026 completion). Its status may not reflect the trial's current state.
Summary
This is a clinical trial in patients with advanced hepatocellular carcinoma (HCC) and Child-Pugh Class B7 (CPB7) cirrhosis whose disease has progressed on at least 1st-line therapy. The trial will evaluate the efficacy and safety of namodenoson as compared to placebo.
Protocol Amendment History 9 amendments
This ClinicalTrials.gov record has been amended 9 times since 2022-01-07; most recent amendment 2025-04-28.
Status change: Not Yet Recruiting → Recruiting 2023-06-15
Trial Details
NCT Number NCT05201404
Lead Sponsor Can-Fite BioPharma
Conditions Hepatocellular Carcinoma, Cirrhosis
Enrollment 471 participants
Start Date 2023-03-15
Primary Completion 2026-02 (estimated)
Study Completion 2026-10 (estimated)
Updated on ClinicalTrials.gov 2025-04-29